Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

Inclusion Criteria: * Diagnosed with type 2 diabetes for a minimum of 6 months prior to Visit 1 * HbA1c at least 7.0 % - maximum 11 % at screening * Subject is insulin naïve (short-term insulin treatment of up to 14 days is allowed) * An antidiabetic regimen that has been stable for at least 3 months prior to screening * An antidiabetic regimen that includes a minimum of 2 OADs * OADs dosed at least 50% of the maximum recommended dose Exclusion Criteria: * Known or suspected hypersensitivity to trial product(s) or related products * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) * The receipt of any investigational medicinal product within one month prior to this trial * Suffer from a life threatening disease (cancer) * Cardiac disease: class III or IV congestive heart failure (CHF), unstable angina, and or any myocardial infarction (treated or untreated) within 6 months prior to screening * Hepatic insufficiency (Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 2 times the central laboratory's upper reference limit) * Renal insufficiency (serum creatinine above 1.6 mg/dl for males; 1.4 mg/dl for females * Recurrent hypoglycaemia or hypoglycaemic unawareness * Anemia (haemoglobin below 10 mg/dl)